Salustiano brings with him over 20 years of experience from all facets of the pharmaceutical industry. Throughout his career, Salustiano has spent several years in different multifunctional leadership roles. He has led the charge to success as the head of business in Brazil, Mexico & Central America for Exeltis, from 2008 to 2015, as well as Commercial Global Director of Chemo from 2015 to 2018. Today Salustiano provides his strategic expertise to pave the way forward as Xiromed continues to surpass its objective of offering high quality and value-added generic products over a broad range of dosage forms and technologies. Salustiano’s positions include time at Sandoz and Abbott, and most applicably as CEO of Exeltis USA since 2018 to date, one of Insud Pharma branded pharmaceutical affiliates. Salustiano received his MBA from Pontificia Universidad Catolica de Chile in 2008.
Susan Stipic-Ryan joined Xiromed® as Senior Director of Retail Sales in June of 2019. Bringing with her over 28 years of experience in the brand and generic pharmaceutical industries, she has held positions of increasing responsibility and continued growth within both the brand and generic sides of the pharmaceutical industry throughout her career. Susan held previous roles at Bristol-Myers Squibb, Kremers Urban Inc., and Amneal Pharmaceuticals as Director of National Accounts. Susan’s focus and expertise lie within the retail space. Susan has been an integral part of helping to build companies from the ground up working in sales, customer strategies, and successfully launching 70+ products during her career. Susan holds her Bachelor of Arts, Communications from Seattle Pacific University.
Rocco Mastrodomenico, Senior Director of Finance, has over 20 years of business experience within the Healthcare and Financial Services industries. Rocco began his career at Deloitte & Touche as an auditor and has held various positions of increasing responsibility in both public accounting and private industry. Rocco worked for Exeltis USA Inc. as Controller and performed post-acquisition integration of all finance functions and was responsible for leading a team through monthly close, annual budgets and financial statements. In 2018 he joined Rising Pharmaceuticals as Director of Finance, where he implemented systems and process improvements, as well as, oversee the day to day functions of the accounting area. Rocco holds his Bachelor of Science degree in Accounting from Babson College and is a Certified Public Accountant.
Donna Genova joined Xiromed® as Vice President Sales & Commercial Operations and brings with her over 25 years of experience in both the generic and branded side of the pharmaceutical industry. Prior to Xiromed®, she most recently held pivotal positions in areas of Institutional and Retail Sales Operations including contracts, pricing, customer strategy, product strategy, sales budgets and forecasts, and new product launches. Earlier in her career, she held positions in financial planning & analysis, budgeting, and sales force effectiveness. Donna’s past industry positions include her tenure at Amneal Pharmaceuticals, Kremers Urban Pharmaceuticals, Lannett Pharmaceuticals, and Bristol Myers Squibb & Sons. Donna holds her Bachelor of Arts degree in Economics and Finance from Douglass College, Rutgers University, and her Masters of Business Administration degree in Finance from Rutgers University Graduate School of Management.
Lisa DiGrazia, Senior Director of US Commercial Strategy, joined Xiromed® with experience as a healthcare professional in a hospital, retail, and pharmaceutical industry settings. Prior to Xiromed®, Lisa worked as a Clinical Oncology Pharmacy Specialist at Rush University Medical Center, where she provided direct patient care and comprehensive clinical services, including overseeing clinical trials and pharmacy policy development. She then joined Amneal Pharmaceuticals to help build a strong and differentiated pipeline of products and support the commercial institutional team with their launch of injectables and biosimilars. Lisa received a PharmD from Midwestern University, Chicago College of Pharmacy. She then completed her internal medicine residency at Rush University Medical Center and her oncology residency at Memorial Sloan Kettering Cancer Center. Her board certifications include Board-Certified Oncology Pharmacist (BCOP) and Board Certified Pharmacotherapy Specialist (BCPS).
David Hernandez, Vice President, Regulatory Strategy, Portfolio, and Business Development, has spent the last 15 years with a specific focus in complex, first to market, generic drugs. As one of Xiromed®’s founding members, David supports the execution, development, and approval of Xiromed®’s R&D pipeline as well as new product launch and business development. Prior to joining Xiromed® in 2015, David led Alvogen’s regulatory strategy and First-to-File generics portfolio. He has also worked in Regulatory Affairs, Compliance, and Quality for Watson (Teva), Nycomed US (Sandoz), and Barr Labs (Teva). David holds a Bachelor's degree in Biology from Purchase College and a Master’s Degree in Regulatory Affairs from Northeastern University.